Abstract
Since the earliest descriptions of Alzheimer ’ s disease (AD), the presence of senile plaques (SP) and neurofibrillary tangles (NFT) have been regarded as the typical pathological hallmarks of the disease. Studies over the last twenty years, however, have reported a considerable degree of heterogeneity within the AD phenotype and as a consequence, an overlap between the pathological features of AD not only with normal aging, but also with disorders related to AD. This review discusses: 1) the degree of heterogeneity within AD, 2) the concept of an ‘interface’ between disorders, 3) the nature and degree of the interface between AD and normal aging, vascular dementia (VD), the tauopathies, synucleinopathies, and prion disease, and 4) whether the original status of AD should be retained or whether AD, normal aging, and the related disorders should be regarded as representing a ‘continuum’ of neuropathological change.
Keywords: Alzheimer's disease (AD), brain lesion, continuum, disease heterogeneity, tauopathy, synucleinopathy, prion disease
Current Aging Science
Title: The Interface Between Alzheimers Disease, Normal Aging, and Related Disorders
Volume: 1 Issue: 2
Author(s): R. A. Armstrong
Affiliation:
Keywords: Alzheimer's disease (AD), brain lesion, continuum, disease heterogeneity, tauopathy, synucleinopathy, prion disease
Abstract: Since the earliest descriptions of Alzheimer ’ s disease (AD), the presence of senile plaques (SP) and neurofibrillary tangles (NFT) have been regarded as the typical pathological hallmarks of the disease. Studies over the last twenty years, however, have reported a considerable degree of heterogeneity within the AD phenotype and as a consequence, an overlap between the pathological features of AD not only with normal aging, but also with disorders related to AD. This review discusses: 1) the degree of heterogeneity within AD, 2) the concept of an ‘interface’ between disorders, 3) the nature and degree of the interface between AD and normal aging, vascular dementia (VD), the tauopathies, synucleinopathies, and prion disease, and 4) whether the original status of AD should be retained or whether AD, normal aging, and the related disorders should be regarded as representing a ‘continuum’ of neuropathological change.
Export Options
About this article
Cite this article as:
Armstrong A. R., The Interface Between Alzheimers Disease, Normal Aging, and Related Disorders, Current Aging Science 2008; 1 (2) . https://dx.doi.org/10.2174/1874609810801020122
DOI https://dx.doi.org/10.2174/1874609810801020122 |
Print ISSN 1874-6098 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-6128 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adult Hippocampal Neurogenesis, Aging and Neurodegenerative Diseases: Possible Strategies to Prevent Cognitive Impairment
Current Topics in Medicinal Chemistry (-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer’s Disease
Current Alzheimer Research Following Intracellular Cholesterol Transport by Linear and Non-Linear Optical Microscopy of Intrinsically Fluorescent Sterols
Current Pharmaceutical Biotechnology Assessing Schizophrenia-relevant Cognitive and Social Deficits in Mice: A Selection of Mouse Behavioral Tasks and Potential Therapeutic Compounds
Current Pharmaceutical Design Mechanisms of ERK1/2 Regulation by Seven-Transmembrane-Domain Receptors
Current Pharmaceutical Design Molecular Mechanisms, Proteinopathies and Therapeutic Strategies in Neurodegenerative Disorders
Current Genomics Central Nervous System Depressants and Risk of Hospitalization due to Community-Acquired Pneumonia in very Old Patients
Current Drug Safety Selection of Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention
Current Pharmaceutical Design Neuroprotective Strategies for Parkinsons Disease
Current Neuropharmacology Evaluating Protein-protein Interaction (PPI) Networks for Diseases Pathway, Target Discovery, and Drug-design Using `In silico Pharmacology`
Current Protein & Peptide Science Obstacles and Opportunities for Cholinergic Drug Development in the Treatment of Cognitive Disorders
Current Pharmaceutical Design O-GlcNAc Modification and the Tauopathies: Insights from Chemical Biology
Current Alzheimer Research Computational Models of Neuronal Biophysics and the Characterization of Potential Neuropharmacological Targets
Current Medicinal Chemistry Nocturnal Blood Pressure Abnormalities in Obstructive Sleep Apnea - Clinical Predictors
Current Respiratory Medicine Reviews Gene Therapy as a Novel Pharmaceutical Intervention for Stroke
Current Pharmaceutical Design Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors
Current Medicinal Chemistry Mitochondrial Abnormalities in a Streptozotocin-Induced Rat Model of Sporadic Alzheimer's Disease
Current Alzheimer Research Genetic Causes of Alzheimer’s Disease and the Neuroprotective Role of Melatonin in its Management
CNS & Neurological Disorders - Drug Targets Re-Balancing of Inflammation and Aβ Immunity as a Therapeutic for Alzheimers Disease-View from the Bedside
CNS & Neurological Disorders - Drug Targets TiO2-Nanowired Delivery of Mesenchymal Stem Cells Thwarts Diabetes- Induced Exacerbation of Brain Pathology in Heat Stroke: An Experimental Study in the Rat Using Morphological and Biochemical Approaches
CNS & Neurological Disorders - Drug Targets